Stay updated with breaking news from Nasdaq Acad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Robert W. Baird initiated coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report released on Tuesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $40.00 price objective on the biopharmaceutical company’s stock. Other equities analysts have also recently issued reports about the company. Citigroup initiated coverage on […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Research analysts at Zacks Research raised their Q4 2024 EPS estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Wednesday, January 31st. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of $0.24 for the quarter, […]
Van Hulzen Asset Management LLC grew its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 83.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 53,070 shares of the biopharmaceutical company’s stock after buying an additional 24,180 shares during the quarter. Van Hulzen Asset Management LLC’s […]
Needham & Company LLC upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a hold rating to a buy rating in a report published on Wednesday morning, Marketbeat reports. They currently have $37.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages also recently commented on ACAD. Deutsche Bank Aktiengesellschaft began […]
Jackson Creek Investment Advisors LLC lessened its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 31.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,431 shares of the biopharmaceutical company’s stock after selling 14,964 shares during the quarter. […]